The adeno-associated viral (AAV) vector production process generates capsids that contain the desired nucleic acid as well as capsids that are empty or partially filled. Empty or partially filled capsids provide no therapeutic benefit and may also contribute to the development of an immune response in patients receiving the therapy.
A number of strategies are available for the capture and separation of full capsids from those that are empty or partially filled.
Sign In To Continue
To continue reading please sign in or create an account.
Don't Have An Account?